What is another name for acalabrutinib?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternative Names for Acalabrutinib

Acalabrutinib is marketed under the brand name Calquence®. 1, 2

Brand and Chemical Names

  • Brand name: Calquence® 1, 2
  • Chemical name: 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide (2Z)-2-butenedioic acid hydrate 1
  • Salt form: Acalabrutinib maleate 1
  • Development code: ACP-196 3

Active Metabolite

  • Major active metabolite: ACP-5862 (also known as M27), which is a pyrrolidine ring-opened ketone/amide derivative that contributes to the clinical efficacy of acalabrutinib 4
  • ACP-5862 is formed through CYP3A4-mediated metabolism and demonstrates potent and selective covalent BTK inhibition, with only twofold lower potency than the parent compound 4

Drug Classification

  • Pharmacological class: Bruton tyrosine kinase (BTK) inhibitor 1, 3
  • Generation: Second-generation BTK inhibitor, designed to be more selective and potent than the first-generation agent ibrutinib 3

References

Related Questions

What is the recommended use and dosing of Acalabrutinib (Acalabrutinib) for adult patients with mantle cell lymphoma or chronic lymphocytic leukemia who have received prior therapy?
What is the recommended use and dosage of Acalabrutinib (Calquence) for mantle cell lymphoma and chronic lymphocytic leukemia?
Does Acalabrutinib (Bruton's tyrosine kinase inhibitor) cause impaired renal function?
What are the considerations for using Calquence (acalabrutinib) in adults with mantle cell lymphoma or chronic lymphocytic leukemia?
What are the adverse effects of Calquence (acalabrutinib) and the recommended monitoring and management strategies?
Can acalabrutinib cause an increase in the white blood cell count?
What is the first-line treatment for peripheral edema and ascites in a patient with cirrhosis?
How should I manage a 2‑year‑old male with serum iron 59 µg/dL, transferrin saturation 14 %, ferritin 66 ng/mL, and unsaturated iron‑binding capacity 348 µg/dL?
What is the appropriate diagnosis and management for an irregular hypoechoic lesion in the right breast of a patient with American College of Radiology (ACR) type B (scattered fibroglandular tissue) breast composition, classified as Breast Imaging Reporting and Data System (BI‑RADS) category 4B (moderately suspicious)?
Can I initiate combination therapy with perindopril 4 mg orally once daily and amlodipine 5 mg orally once daily in a patient with severely elevated blood pressure?
What is the cause of Q waves in the precordial leads V3‑V6?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question